AR047744A1 - Compuestos de triazol y su uso como antagonistas del receptor de glutamato metabotropico - Google Patents
Compuestos de triazol y su uso como antagonistas del receptor de glutamato metabotropicoInfo
- Publication number
- AR047744A1 AR047744A1 ARP050100570A ARP050100570A AR047744A1 AR 047744 A1 AR047744 A1 AR 047744A1 AR P050100570 A ARP050100570 A AR P050100570A AR P050100570 A ARP050100570 A AR P050100570A AR 047744 A1 AR047744 A1 AR 047744A1
- Authority
- AR
- Argentina
- Prior art keywords
- 6alkyl
- 4alkyl
- nr5r6
- group
- 6alkylnr5
- Prior art date
Links
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical class C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 title 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 229930195712 glutamate Natural products 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 11
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 6
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 229910052760 oxygen Inorganic materials 0.000 abstract 5
- 229910052717 sulfur Inorganic materials 0.000 abstract 5
- -1 OC1-6alkyl Chemical group 0.000 abstract 4
- 125000003118 aryl group Chemical group 0.000 abstract 4
- 229910052799 carbon Inorganic materials 0.000 abstract 4
- 125000001475 halogen functional group Chemical group 0.000 abstract 4
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 4
- 229910052757 nitrogen Inorganic materials 0.000 abstract 4
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 3
- 125000002877 alkyl aryl group Chemical group 0.000 abstract 3
- 125000004429 atom Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 3
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 1
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 abstract 1
- 125000005213 alkyl heteroaryl group Chemical group 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Compuestos, o sales o hidratos, procesos para su preparacion intermediarios usados en su preparacion, composiciones farmacéuticas que contienen dichos compuestos y el uso terapéutico de los mismos. Reivindicacion 1: Un compuesto caracterizado porque responde a la formula (1), en donde: P es arilo; si m = 1 entonces R1 se une a P en la posicion meta del anillo P respecto del punto de union de P con el anillo de 5 miembros, y si m = 2 entonces R1 se une a P en las posiciones 2 y 5 del anillo P con el anillo de 5 miembros; R1 se selecciona entre el grupo formado por hidroxi, halo, nitro, C1-6 alquilhalo, OC1-6alquilhalo, C1-6 alquilo, OC1-6alquilo, C2-6 alquenilo, OC2-6alquenilo, C2-6 alquinilo, OC2-6alquinilo, C0-6alquilC3- 6cicloalquilo, OC0-6alquilC3-6cicloalquilo, C0-6 alquilarilo, OC0-6alquilarilo, CHO, (CO)R5, O(CO)R5, O(CO)OR5, O(CN)OR5, C1-6alquilOR5, OC2-6alquilOR5, C1-6alquil(CO)R5, OC1-6alquil(CO)R5, C0-6alquilCO2R5, OC1-6alquilCO2R5, C0-6 alquilciano, OC2- 6alquilciano, C0-6alquilNR5R6, OC2-6alquilNR5R6, C1-6alquil(CO)NR5R6, OC1-6alquil(CO)NR5R6, C0-6alquilNR5(CO)R6, OC2-6alquilNR5(CO)R6, C0-6alquilNR5(CO)NR5R6, C0-6alquilSR5, OC2-6alquilSR5, C0-6alquil(SO)R5, OC2-6alquil(SO)R5, C0-6alquilSO2R5, OC2- 6alquilSO2R5, C0-6alquil(SO2)NR5R6, OC2-6alquil(SO2)NR5R6, C0-6alquilNR5(SO2)R6, OC2-6alquilNR5(SO2)R6, C0-6alquilNR5(SO2)NR5R6, OC2-6alquilNR5(SO2)NR5R6, (CO)NR5R6, O(CO)NR5R6, NR5OR6, C0-6alquilNR5(CO)OR6, OC2-6alquilNR5(CO)OR6, SO3R5 y un anillo de 5 o 6 miembros que contiene átomos seleccionados en forma independiente entre el grupo formado por C, N, O y S; R5 y R6 se seleccionan en forma independiente entre un grupo formado por hidrogeno, C1-6 alquilo, C3-7 cicloalquilo y arilo; X1 y X2 se seleccionan en forma independiente entre el grupo formado por CR4, y N; X3 se selecciona entre el grupo formado por CR4, N y O; en donde al menos uno de X1, X2 y X3 no es N; R4 se selecciona entre el grupo formado por H, =O, C1-6 alquilo, OH; R3 se selecciona entre el grupo formado por H, C1-6 alquilo, hidroxi, C0-6 alquilciano, oxo, =NR5, =NOR5, C1-4 alquilhalo, halo, C3-7 cicloalquilo, O(CO)C1-4alquilo, C1-4alquil(SO)C0-4alquilo, C1-4alquil(SO2)C0-4alquilo, (SO)C0-4alquilo, (SO2)C0- 4alquilo, OC1-4alquilo, C1-4alquilOR5 y C0-4alquilNR5R6; X4 se selecciona entre el grupo formado por CR7R8, NR7, O, S, SO y SO2; R7 y R8 se seleccionan en forma independiente entre un grupo formado por hidrogeno, C1-6 alquilo, C3-7 cicloalquilo y arilo; X5 y X6 se seleccionan en forma independiente entre el grupo formado por C, N, O y S; R2 se selecciona entre el grupo formado por hidroxi, C0-6 alquilciano, =NR5, =NOR5, C1-4 alquilhalo, halo, C1-6 alquilo, C3-6 cicloalquilo, C0-6 alquilarilo, C0-6 alquilheteroarilo, C0-6 alquilcicloalquilo, C0-6 alquilheterocicloalquilo, OC1-4alquilo, OC0-6alquilarilo, O(CO)C1-4alquilo, (CO)OC1-4alquilo, C0-4alquil(S)C0-4alquilo, C1-4alquil(SO)C0-4alquilo, C1-4alquil(SO2)C0-4alquilo, (SO)C0- 4alquilo, (SO2)C0-4alquilo, C1-4alquilOR5, C0-4alquilNR5R6 y un anillo de 5 o 6 miembros que contiene átomos seleccionados en forma independiente entre C, N, O y S, y en donde dicho anillo puede sustituirse con uno o más A; y cualquier C1-6 alquilo, arilo o heteroarilo definido bajo R1, R2 y R3 puede sustituirse con uno o más A; A se selecciona entre el grupo formado por hidrogeno, hidroxi, halo, nitro, oxo, C0-6 alquilciano, C0-4alquilC3-6cicloalquilo, C1-6 alquilo, C1-6 alquilhalo, OC1- 6alquilhalo, C2-6 alquenilo, C0-3 alquilarilo, C0-6alquilOR5, OC2-6alquilOR5, C1-6alquilSR5, OC2-6alquilSR5, (CO)R5, O(CO)R5, OC2-6alquilciano, OC1-6alquilCO2R5, O(CO)OR5, OC1-6alquil(CO)R5, C1-6alquil(CO)R5, NR5OR6, C1-6alquilNR5R6, OC2- 6alquilNR5R6, C0-6alquil(CO)NR5R6, OC1-6alquil(CO)NR5R6, OC2-6alquilNR5(CO)R6, C0-6alquilNR5(CO)R6, C0-6alquilNR5(CO)NR5R6, O(CO)NR5R6, C0-6alquil(SO2)NR5R6, OC2-6alquil(SO2)NR5R6, C0-6alquilNR5(SO2)R6, OC2-6alquilNR5(SO2)R6, SO3R5, C1- 6alquilNR5(SO2)NR5R6, OC2-6alquil(SO2)R5, C0-6alquil(SO2)R5, C0-6alquil(SO)R5, OC2-6alquil(SO)R5 y un anillo de 5 o 6 miembros que contiene uno o más átomos seleccionados en forma independiente entre el grupo formado por C, N, O y S; m se selecciona entre 1 y 2; n se selecciona entre 0, 1, 2, 3 y 4; p se selecciona entre 1 y 2; y sus sales de hidratos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54528904P | 2004-02-18 | 2004-02-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR047744A1 true AR047744A1 (es) | 2006-02-15 |
Family
ID=34886127
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050100570A AR047744A1 (es) | 2004-02-18 | 2005-02-17 | Compuestos de triazol y su uso como antagonistas del receptor de glutamato metabotropico |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20070185178A1 (es) |
| EP (1) | EP1720860A1 (es) |
| JP (1) | JP2007523178A (es) |
| KR (1) | KR20070027503A (es) |
| CN (1) | CN101018779A (es) |
| AR (1) | AR047744A1 (es) |
| AU (1) | AU2005214375A1 (es) |
| BR (1) | BRPI0507501A (es) |
| CA (1) | CA2554894A1 (es) |
| EA (1) | EA200601266A1 (es) |
| IL (1) | IL177057A0 (es) |
| NO (1) | NO20063468L (es) |
| RU (1) | RU2006127575A (es) |
| TW (1) | TW200604183A (es) |
| UY (1) | UY28760A1 (es) |
| WO (1) | WO2005080379A1 (es) |
| ZA (1) | ZA200606313B (es) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006080533A1 (ja) * | 2005-01-31 | 2006-08-03 | Mochida Pharmaceutical Co., Ltd. | ３－アミノ－１,２,４－トリアゾール誘導体 |
| AR058807A1 (es) | 2005-09-29 | 2008-02-27 | Astrazeneca Ab | 5-(fenilisoxazoletoxi)-triazol-3-il piridinas sustituidas, para el tratamiento de trastornos mediados por el receptor mglur5 |
| TW200811156A (en) * | 2006-05-05 | 2008-03-01 | Astrazeneca Ab | mGluR5 modulators IV |
| AR068921A1 (es) * | 2007-10-19 | 2009-12-16 | Astrazeneca Ab | Derivados heterociclicos de tetrazol y 1,2-4 triazoles, composiciones farmaceuticas que los contienen y usos de los mismos para tratar desordenes neurologicos, gastrointestinales y del dolor,entre otros. |
| WO2009054790A1 (en) * | 2007-10-26 | 2009-04-30 | Astrazeneca Ab | Amide linked heteroaromatic derivatives as modulators of mglur5 |
| WO2009054785A1 (en) * | 2007-10-26 | 2009-04-30 | Astrazeneca Ab | 1,2,4-triazole ether derivatives as modulators of mglur5 |
| TW200922585A (en) * | 2007-10-26 | 2009-06-01 | Astrazeneca Ab | Amino 1,2,4-triazole derivatives as modulators of mGluR5 |
| CN101643451B (zh) * | 2008-08-07 | 2013-03-06 | 浙江海正药业股份有限公司 | 过氧化物酶增殖物激活受体亚型δ类激动剂化合物及其制备方法 |
| US20100114146A1 (en) * | 2008-10-30 | 2010-05-06 | Albrecht Thomas E | Methods and devices for predicting intra-gastric satiety and satiation creation device system performance |
| WO2010068172A1 (en) * | 2008-12-12 | 2010-06-17 | Astrazeneca Ab | A new process for preparing 4- [4-methyl-5- (cl- 10alkylthio/c5-10aryl-cl-6alkylthio) -4h-1, 2, 4-triazol-3- yl] pyridines. |
| JP2012512868A (ja) * | 2008-12-18 | 2012-06-07 | アストラゼネカ・アクチエボラーグ | ３−｛４−メチル−５−［（１ｒ）−１−（２−（３−メチルフェニル−２ｈ−テトラゾール−５−イル）−エトキシ］−４ｈ−［１，２，４］トリアゾール−３−イル｝−ピリジン、４−メチル−３−メチルチオ−５−（３−ピリジル）−１，２，４−トリアゾール、および（１ｒ）−１−［２−（３−メチルフェニル）−２ｈ−テトラゾール−５−イル］エタノールの製造方法 |
| US8349852B2 (en) | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
| US20100273805A1 (en) * | 2009-04-23 | 2010-10-28 | Astrazeneca Ab | Sulphide bridged derivatives as modulators of mglur5 733 |
| US20120295942A1 (en) | 2010-02-01 | 2012-11-22 | Nicholas James Devereux | Pyrazolo[5,1b]oxazole Derivatives as CRF-1 Receptor Antagonists |
| AR080056A1 (es) | 2010-02-01 | 2012-03-07 | Novartis Ag | Derivados de ciclohexil-amida como antagonistas de los receptores de crf |
| CN102753527B (zh) | 2010-02-02 | 2014-12-24 | 诺华股份有限公司 | 用作crf受体拮抗剂的环己基酰胺衍生物 |
| CA2815741A1 (en) * | 2010-11-09 | 2012-05-18 | F. Hoffmann-La Roche Ag | Triazole derivatives as ligands for gaba receptors |
| WO2013134562A1 (en) | 2012-03-09 | 2013-09-12 | Inception 2, Inc. | Triazolone compounds and uses thereof |
| DK2935228T3 (en) | 2012-12-20 | 2017-10-30 | Inception 2 Inc | TRIAZOLONE COMPOUNDS AND APPLICATIONS THEREOF |
| WO2015035059A1 (en) | 2013-09-06 | 2015-03-12 | Inception 2, Inc. | Triazolone compounds and uses thereof |
| WO2015057655A1 (en) | 2013-10-14 | 2015-04-23 | Eisai R&D Management Co., Ltd. | Selectively substituted quinoline compounds |
| KR101823488B1 (ko) | 2013-10-14 | 2018-01-30 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 선택적으로 치환된 퀴놀린 화합물 |
| ES2791186T3 (es) | 2014-08-15 | 2020-11-03 | Janssen Pharmaceuticals Inc | Triazoles como inhibidores de receptores NR2B |
| PL3180315T3 (pl) | 2014-08-15 | 2020-09-07 | Janssen Pharmaceuticals, Inc. | Pirazole |
| HRP20200410T1 (hr) | 2015-07-09 | 2020-08-21 | Janssen Pharmaceutica Nv | Supstituirani 4-azaindoli i njihova upotreba kao modulatora glun2b receptora |
| EA201891799A1 (ru) * | 2016-02-10 | 2019-02-28 | Янссен Фармацевтика Нв | Замещенные 1,2,3-триазолы в качестве nr2b-селективных модуляторов nmda |
| AR108838A1 (es) | 2016-06-21 | 2018-10-03 | Bristol Myers Squibb Co | Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa |
| TW201819376A (zh) | 2016-10-06 | 2018-06-01 | 比利時商健生藥品公司 | 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途 |
| AU2018346597B2 (en) | 2017-10-06 | 2023-07-13 | Forma Therapeutics, Inc. | Inhibiting Ubiquitin Specific Peptidase 30 |
| US11008302B2 (en) | 2018-04-04 | 2021-05-18 | Janssen Pharmaceutica Nv | Substituted pyridine and pyrimidines and their use as GluN2B receptor modulators |
| WO2019222468A1 (en) | 2018-05-17 | 2019-11-21 | Forma Therapeutics, Inc. | Fused bicyclic compounds useful as ubiquitin-specific peptidase 30 inhibitors |
| FI3860989T3 (fi) | 2018-10-05 | 2023-05-25 | Forma Therapeutics Inc | Ubikitiinispesifisen proteaasi 30:n (usp30) inhiboiminen |
| WO2020113094A1 (en) | 2018-11-30 | 2020-06-04 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| PH12021552839A1 (en) | 2019-06-14 | 2022-10-03 | Janssen Pharmaceutica Nv | Substituted pyrazolo-pyridine amides and their use as glun2b receptor modulators |
| BR112021025132A2 (pt) | 2019-06-14 | 2022-01-25 | Janssen Pharmaceutica Nv | Carbamatos de piridina e seu uso como moduladores do receptor glun2b |
| EP3983073A1 (en) | 2019-06-14 | 2022-04-20 | Janssen Pharmaceutica NV | Substituted pyrazolo[4,3-b]pyridines and their use as glun2b receptor modulators |
| KR20220020915A (ko) | 2019-06-14 | 2022-02-21 | 얀센 파마슈티카 엔.브이. | GluN2B 수용체 조절제로서의 피라진 카르바메이트 및 이들의 용도 |
| SG11202112405VA (en) | 2019-06-14 | 2021-12-30 | Janssen Pharmaceutica Nv | Substituted heteroaromatic pyrazolo-pyridines and their use as glun2b receptor modulators |
| AU2020292994A1 (en) | 2019-06-14 | 2022-01-06 | Janssen Pharmaceutica Nv | Substituted pyrazolo-pyrazines and their use as GluN2B receptor modulators |
| JOP20210328A1 (ar) | 2019-06-14 | 2023-01-30 | Janssen Pharmaceutica Nv | مركبات أميدات بيريدين-بيرازولو المستبدلة واستخدامها باعتبارها معدِّلات لمستقبل الغلوتومات "glun2b" |
| CN110669017B (zh) * | 2019-10-11 | 2023-08-04 | 成都麻沸散医药科技有限公司 | 多取代三唑甲酸酯类衍生物及其用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003029210A2 (en) * | 2001-10-04 | 2003-04-10 | Merck & Co. Inc. | Heteroaryl substituted tetrazole modulators of metabotropic glutamate receptor-5 |
| EP1451160B1 (en) * | 2001-11-01 | 2010-01-13 | Icagen, Inc. | Pyrazole-amides for use in the treatment of pain |
| EP1485093B1 (en) * | 2002-03-12 | 2010-11-03 | Merck Sharp & Dohme Corp. | Di-aryl substituted tetrazole modulators of metabotropic glutamate receptor-5 |
| JP2006502134A (ja) * | 2002-08-09 | 2006-01-19 | アストラゼネカ アクチボラグ | 代謝調節型グルタミン酸受容体において活性を有する化合物 |
| AR040847A1 (es) * | 2002-08-09 | 2005-04-20 | Astrazeneca Ab | 1,2,4-oxadiazoles como moduladores de receptores de glutamato metabotropicos, para el tratamiento de desordenes neurologicos y psiquiatricos |
-
2005
- 2005-02-17 EP EP05723281A patent/EP1720860A1/en not_active Withdrawn
- 2005-02-17 RU RU2006127575/04A patent/RU2006127575A/ru not_active Application Discontinuation
- 2005-02-17 CN CNA2005800102818A patent/CN101018779A/zh active Pending
- 2005-02-17 US US10/588,751 patent/US20070185178A1/en not_active Abandoned
- 2005-02-17 BR BRPI0507501-7A patent/BRPI0507501A/pt not_active IP Right Cessation
- 2005-02-17 CA CA002554894A patent/CA2554894A1/en not_active Abandoned
- 2005-02-17 WO PCT/US2005/005200 patent/WO2005080379A1/en active Application Filing
- 2005-02-17 TW TW094104645A patent/TW200604183A/zh unknown
- 2005-02-17 JP JP2006554231A patent/JP2007523178A/ja active Pending
- 2005-02-17 AU AU2005214375A patent/AU2005214375A1/en not_active Abandoned
- 2005-02-17 AR ARP050100570A patent/AR047744A1/es not_active Application Discontinuation
- 2005-02-17 EA EA200601266A patent/EA200601266A1/ru unknown
- 2005-02-17 KR KR1020067015941A patent/KR20070027503A/ko not_active Withdrawn
- 2005-02-18 UY UY28760A patent/UY28760A1/es unknown
- 2005-02-18 US US11/060,366 patent/US20060019997A1/en not_active Abandoned
-
2006
- 2006-07-25 IL IL177057A patent/IL177057A0/en unknown
- 2006-07-28 NO NO20063468A patent/NO20063468L/no not_active Application Discontinuation
- 2006-07-28 ZA ZA200606313A patent/ZA200606313B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN101018779A (zh) | 2007-08-15 |
| RU2006127575A (ru) | 2008-03-27 |
| US20060019997A1 (en) | 2006-01-26 |
| IL177057A0 (en) | 2006-12-10 |
| EP1720860A1 (en) | 2006-11-15 |
| AU2005214375A1 (en) | 2005-09-01 |
| NO20063468L (no) | 2006-11-15 |
| UY28760A1 (es) | 2005-06-30 |
| EA200601266A1 (ru) | 2007-02-27 |
| ZA200606313B (en) | 2007-03-28 |
| JP2007523178A (ja) | 2007-08-16 |
| CA2554894A1 (en) | 2005-09-01 |
| BRPI0507501A (pt) | 2007-06-26 |
| TW200604183A (en) | 2006-02-01 |
| US20070185178A1 (en) | 2007-08-09 |
| KR20070027503A (ko) | 2007-03-09 |
| WO2005080379A1 (en) | 2005-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR047744A1 (es) | Compuestos de triazol y su uso como antagonistas del receptor de glutamato metabotropico | |
| AR047812A1 (es) | Compuestos de tetrazol y su uso como antagonistas del receptor de glutamato metabotropico | |
| AR066562A1 (es) | Derivados de pirrol condensados; una formulacion farmaceutica en base al compuesto y su uso para preparar medicamentos | |
| PE20221253A1 (es) | Inhibidores de pequenas moleculas de mutante g12c de kras | |
| AR061923A1 (es) | Compuestos derivados de benzofuran-piperidina | |
| AR059176A1 (es) | Compuesto de indol, composicion farmaceutica que lo comprende, metodo para prepararlo y su uso para preparar dicha composicion y para la manufactura de un medicamento para el tratamiento o prevencion de leiomiomas y endometriosis. | |
| AR057987A1 (es) | Compuestos agonistas de cb1 (receptor cannabinoide) | |
| AR054529A1 (es) | Derivados de benzazepina como moduladores del receptor de 5-hidroxi-triptamina 6 | |
| PE20060691A1 (es) | Serinamidas sustituidas por benzoilo | |
| AR052458A1 (es) | Amino-imidazolonas para la inhibicion de beta-secretasa | |
| CO6220949A2 (es) | Derivados pirazolicos como inhibidores de la 11 beta -hsd1 | |
| AR040847A1 (es) | 1,2,4-oxadiazoles como moduladores de receptores de glutamato metabotropicos, para el tratamiento de desordenes neurologicos y psiquiatricos | |
| AR049708A1 (es) | Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos | |
| AR061371A1 (es) | Amino - imidazolonas y su uso como medicamento para la enfermedad de alzheimer y otras enfermedades neurodegenerativas. | |
| AR082562A1 (es) | Derivados de isoxazolina como agentes antiparasitarios | |
| AR088029A1 (es) | Compuestos de pirimidina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del dolor, accidentes cerebrovasculares, epilepsia y otras enfermedades del sistema nervioso central | |
| AR085960A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
| AR049388A1 (es) | Heterociclos como inhibidores de aldosterona sintasa | |
| AR056103A1 (es) | Compuestos de(piran-piperidinil)benzimidazol, composiciones farmaceuticas que los comprenden, proceso de preparacion y usos en el tratamiento de afecciones mediadas por agonistas del receptor muscarinico m1 | |
| AR061369A1 (es) | Derivados de pirimidina y composiciones farmaceuticas que los comprenden | |
| AR048289A1 (es) | Eteres de anillos imidazo sulfona sustituidos. | |
| AR049331A1 (es) | Derivados de imidazopiridinas, imidazoquinolinas e iimidazonaftiridinas sustituidas con amidas como moduladores de biosintesis de citoquinas. composiciones farmaceuticas. | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| PE20200664A1 (es) | Compuestos espirociclicos y sus metodos de preparacion y uso | |
| AR075084A1 (es) | Metodo de preparacion de quinolinil -oxidifenil - ciclopropanodicarboxamidas e intermediarios correspondientes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |